Shagun Singh

When in 2027, would you expect that transition to kind of complete?

if there is any negative impact we should expect given oral GLP-1s, et cetera, to your pharmaceutical business

how should we think about Alaris beyond this year? Do you get to that 5% or mid-single digits next year? Or will Alaris be a headwind?

Could you talk about the right growth rate in your view for your U.S. and OUS business excluding Stello

Jake, can you share with us what your vision for DexCom is, what you plan to do similarly or differently to define your era at DexCom

I was hoping you could walk us through some of the assumptions behind the 14% growth rate for 2025

within the high-risk population, we could see up to a 30% reduction. How does that compare with your expectation

should we think about MedTech as a high single-digit growth contributor towards the double-digit growth

could you spend some time and elaborate on your next step with respect to the tax litigation, you know, implications of the initial Robert decision

what gets you to exceed those levels? And as we think about 2026, why is 5% a good number given that you have easy comps?

if you could share some feedback that you're getting from doctors around appetite for adoption

as you think about growth should we think about Medtronic moving towards that high single digit on the top line?

how should we think about your portfolio management strategy going forward?

Can you talk about the mix of cryo? It seems like it's becoming less and less of a headwind. Any color on pricing there?

you could put maybe a finer point. Some of the drivers here could be pretty meaningful. So anything you can share here in terms of magnitude of the incremental growth contribution

what are your thoughts on tariffs? How do you plan to navigate your supply chain? And perhaps you can touch on your exposure to imports from China?

The $10 million in revenue that shifted into Q1. Can you just elaborate on what the nature of that was

can you maybe just elaborate on some of the assumptions behind the 2025 guidance? What drives the step down in Q2? Is it conservatism or are there other factors to consider

what are the learnings from the cyberattack to prevent something like this in the future

I don't know if you can directionally tell us how much is deferred procedures versus production delays

Where do you think these metrics go over time? And what are the key drivers there

it seems like a step down in the back half versus front half on an adjusted basis, still really strong, but just wondering if it's conservatism

On international, you indicated that it could be a significant catalyst for future growth. I'm wondering if you can elaborate on that

how should we think about that weighted average market growth going forward? And then just similarly on margins, you guys had previously said at least 30 basis points annually beyond 2025

Can you maybe give us a little bit more on the confidence you have in the progress on the fully autonomous portion of the robot

how are you thinking about further boosting your position in the ASCs, and then also expanding potentially into new adjacencies